middle.news
Cyclopharm’s Technegas and AI Target New COPD Treatment Frontier
8:38am on Thursday 29th of January, 2026 AEDT
•
Healthcare
Read Story
Cyclopharm’s Technegas and AI Target New COPD Treatment Frontier
8:38am on Thursday 29th of January, 2026 AEDT
Key Points
New ESSA Study targets severe COPD patients beyond current valve therapy eligibility
Technegas functional lung imaging integrated with AI from Thirona for precise treatment guidance
Minimally invasive segmental lung volume reduction using polymer foam
Single-centre, controlled study at Macquarie University Hospital with 34 patients
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
CYCLOPHARM (ASX:CYC)
OPEN ARTICLE